Sensors are applied to the heart and sensor data is supplied to a rules engine. The rules engine applies rules that reflect a CRM pharmaceutical regime of the patient to the sensor data to determine whether an electrical waveform should be applied to the heart. When electrical stimulation is warranted, the drug awareness rules are used by the rules engine to instruct a multi-phase cardiac stimulus generator to generate an electrical waveform that improves the performance of the drugs administered to the patient, allow the patient to be administered a lower dose of a particular drug, and/or reduce or eliminate side effects from the drugs.

An implantable cardiac system that includes an implantable cardiac pacemaker or leadless pacemaker (iLP) and a second device such as a subcutaneous implantable cardioverter-defibrillator (S-ICD). The pacemaker includes an R-spike amplifier that amplifies stimulated ventricle excitations or R-waves to increase R-wave to T-wave signal to noise ratio and to improve indirect detection of ventricular rhythm classification by the S-ICD. The S-ICD includes an electrode line for defibrillation, a sensing unit and a stimulation detection unit. The S-ICD records a subcutaneous electrocardiogram between shock electrode poles and provides potentially life-saving therapy based thereon. The system significantly increases the specificity and sensitivity of an S-ICD in combination with an implanted cardiac pacemaker or iLP having an R-spike amplifier.

A method for producing cardiomyocyte cells including implanting a substrate within a heart such that a first portion of the substrate is in physical contact with an endocardium and a second portion of the substrate is not in contact with the endocardium, maintaining the first portion of the substrate in contact with the endocardium for a time at least sufficient to form trabecular fibers extending between the endocardium and the second portion of the substrate, cutting away the trabecular fibers from the endocardium, cutting away the trabecular fibers from the substrate, and removing the trabecular fibers from the heart, wherein the trabecular fibers include cardiomyocyte cells.

A medical device of the type used for assisting a user in manually delivering repetitive therapy to a patient (e.g., chest compressions or ventilations in cardiac resuscitation), the device comprising a feedback device configured to generate feedback cues to assist the user in timing the delivery of the repetitive therapy, at least one sensor or circuit element configured to detect actual delivery times, at which the user actually delivers the repetitive therapy, and a processor, memory, and associated circuitry configured to compare the actual delivery times to information representative of desired delivery times to determine cue times at which the feedback cues are generated by the feedback device.

An example medical device includes a plurality of electrodes, therapy delivery circuitry, and processing circuitry configured to control the therapy delivery circuitry to deliver electrical stimulation to an intercostal nerve of a patient via at least two of the plurality of electrodes, wherein the electrical stimulation is delivered with stimulation parameters configured to suppress ventricular tachyarrhythmia of the patient, wherein the stimulation parameters comprise a stimulation frequency less than or equal to 40 hertz (Hz).

A rules engine acquires sensor data from sensors applied to the heart to determine the presence of a rapid heartbeat. The rules engine applies rules to the sensor data to determine whether to deliver an electrical waveform to a vagus nerve. The rules engine further determines whether an electrical waveform should be applied to the heart and, if so, the type of electrical waveform.

A rules engine acquires sensor data from sensors applied to the heart and determines whether an electrical waveform should be applied to the heart and, if so, the type of electrical waveform. A multiphase cardiac stimulus generator generates waveforms in response to the rules engine. The electrical waveform is applied to one or more electrodes implanted in or on the heart.

Sensors are applied to the heart and sensor data is supplied to a rules engine. The rules engine applies rules that reflect a CRM pharmaceutical regime of the patient to the sensor data to determine whether an electrical waveform should be applied to the heart. When electrical stimulation is warranted, the drug awareness rules are used by the rules engine to instruct a multi-phase cardiac stimulus generator to generate an electrical waveform that improves the performance of the drugs administered to the patient, allow the patient to be administered a lower dose of a particular drug, and/or reduce or eliminate side effects from the drugs.

A method of modifying tissue behavior, comprising: determining a desired modification of tissue behavior for at least one of treatment of a disease, short or long term modification of tissue behavior, assessing tissue state and assessing tissue response to stimulation; selecting an electric field having an expected effect of modifying protein activity of at least one protein as an immediate response of a tissue to the field, said expected effect correlated with said desired modification; and applying said field to said tissue.

An implantable cardiac device comprises a device can and a single lead extending from the device can for cardiac emplacement. The lead senses a first cardiac wave propagating along a first vector and the same cardiac wave propagating along a second vector. The first vector may be between first and second locations on the lead, and the second vector between the lead and the device can or involving other locations on the lead so that a second lead is not needed and it is possible to make a single lead device.